首页> 外文OA文献 >Multiple Resistance at No Cost: Rifampicin and Streptomycin a Dangerous Liaison in the Spread of Antibiotic Resistance
【2h】

Multiple Resistance at No Cost: Rifampicin and Streptomycin a Dangerous Liaison in the Spread of Antibiotic Resistance

机译:免费获得多重耐药性:利福平和链霉素是抗生素耐药性传播的危险联络

摘要

Evidence is mounting that epistasis is widespread among mutations. The cost of carrying two deleterious mutations, or the advantage of acquiring two beneficial alleles, is typically lower that the sum of their individual effects. Much less is known on epistasis between beneficial and deleterious mutations, even though this is key to the amount of genetic hitchhiking that may occur during evolution. This is particularly important in the context of antibiotic resistance: Most resistances are deleterious, but some can be beneficial and remarkably rifampicin resistance can emerge de novo in populations evolving without antibiotics. Here we show pervasive positive pairwise epistasis on Escherichia coli fitness between beneficial mutations, which confer resistance to rifampicin, and deleterious mutations, which confer resistance to streptomycin. We find that 65% of double resistant strains outcompete sensitive bacteria in an environment devoid of antibiotics. Weak beneficial mutations may therefore overcome strong deleterious mutations and can even render double mutants strong competitors.
机译:越来越多的证据表明上位性在突变中广泛存在。携带两个有害突变的成本,或获得两个有益等位基因的优势,通常要比它们各自作用的总和低。关于有益突变和有害突变之间的上位性知之甚少,即使这是进化过程中可能发生的遗传搭便车数量的关键。在抗生素耐药性的情况下,这一点尤其重要:大多数耐药性都是有害的,但有些耐药性可能是有益的,并且在没有抗生素的人群中,新出现的利福平耐药性很明显。在这里,我们显示了有益突变(赋予对利福平的抗性)和有害突变(赋予对链霉素的抗性)之间在大肠杆菌适应性上普遍存在的成对阳性上位性。我们发现,在没有抗生素的环境中,有65%的双重耐药菌株胜过敏感细菌。弱的有益突变因此可以克服强大的有害突变,甚至可以使双重突变成为强大的竞争者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号